Also, CEO Jean Jacques Bienaime sold 8,000 shares of BioMarin Pharmaceutical stock in a transaction that occurred on Friday, December 30th. They set a buy rating and a $109.00 target price on the stock. BioMarin
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is well on its way to outperform this year in the biotech sector according to a number of opinions from Wall Street analysts and investors. Recently UBS included BioMarin
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) was downgraded by equities research analysts at Vetr from a “strong-buy” rating to a “buy” rating in a research report issued to clients and investors on Monday. They …
On Dec 28, Zacks Investment Research upgraded BioMarin Pharmaceutical Inc. BMRN by one notch to a Zacks Rank #2 (Buy). Why the Upgrade? BioMarin’s shares have gained 3.8% since the company reported stellar …
BioMarin Pharmaceutical
It was a 3.4% negative revenue surprise that caused a disappointment on Wall Street. BioMarin stock closed at $81.02 on October 27, 2016, from the earlier day’s closing price of $81.75. Perhaps a positive earnings …
Earnings
BioMarin's stock has fallen this year, down more than 15 percent. BMRN 2016 Chart Shares of Roche were modestly higher on the day. Roche's stock has also fallen this year, down more than 8 percent.
CNBC8mon
The Company gained 3.69% and finished at $93.76. The daily volume was measured at 1.47 million shares. The 52-week high of the share price is $149.54 and the 52-week low is $62.12. The company has a market cap of …
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) insider Henry J. Fuchs sold 15,000 shares of BioMarin Pharmaceutical stock in a transaction dated Friday, February 24th. The shares were sold at an average price …
Deutsche Bank began its coverage on BioMarin Pharm (NASDAQ:BMRN), today Thursday, 3 November. …
It is very helpful to read a report on BioMarin Pharma stock analysis. An investor must check the following items in an income statement: Revenue: The money received by selling of goods or services comes under this line …